Xinglong Zheng, MD, PhD; Arnel M. Pallera, MD; Lawrence T. Goodnough, MD; J. Evan Sadler, MD, PhD; Morey A. Blinder, MD
Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and Rituximab. Ann Intern Med. 2003;138:105-108. doi: 10.7326/0003-4819-138-2-200301210-00011
Download citation file:
Published: Ann Intern Med. 2003;138(2):105-108.
Thrombotic thrombocytopenic purpura (TTP) in adults is usually caused by autoantibody inhibitors of ADAMTS13. Treatment with plasma exchange is often effective but does not address the underlying autoimmune process.
To report the efficacy of intensive immunosuppressive therapy in refractory TTP.
University medical center.
42-year-old woman with chronic relapsing TTP.
Immunosuppression therapy with rituximab and cyclophosphamide.
ADAMTS13 activity and inhibitors and hematologic variables for TTP.
For 19 months, the patient had relapsing thrombotic microangiopathy despite plasma exchange; splenectomy; and therapy with vincristine, prednisone, and cyclosporine. ADAMTS13 activity was low, and tests detected an IgG inhibitor that recognized the metalloprotease domain of recombinant ADAMTS13. After treatment with rituximab and cyclophosphamide, the disease remitted, ADAMTS13 levels normalized, and the inhibitor was undetectable. The patient has required no treatment for 13 months.
Intensive immunosuppressive therapy can lead to sustained clinical remission in patients with refractory autoimmune TTP.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Platelet Disorders, Coagulopathies.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only